Company Filing History:
1 out of 1 
1 out of 2 
1 out of 11 
Years Active: 2016-2018
Title: Innovations by Chuan Shih: Pioneering Cancer Treatment Solutions
Introduction
Chuan Shih, an accomplished inventor based in Taicang, China, has made significant contributions to the field of pharmaceuticals, particularly in developing innovative treatments for cancer. With a total of three patents to his name, Shih has demonstrated a strong commitment to advancing medical science through his inventive creations.
Latest Patents
Among Chuan Shih's latest patents are two groundbreaking inventions. The first is an ALK kinase inhibitor, which includes a compound represented by Formula I and involves a pharmaceutical composition for preparing drugs aimed at treating cancer by acting as an ALK inhibitor. This invention highlights Shih's focus on targeted cancer therapies. The second patent encompasses highly selective c-Met inhibitors designed as anticancer agents. This patent discloses novel nitrogen-containing, heterocyclic compounds that inhibit c-Met kinase pathway signaling, with great relevance for treating cell proliferative disorders mediated by c-Met.
Career Highlights
Throughout his career, Chuan Shih has aligned with innovative companies to bring his inventions to fruition. Notably, he has worked with Crown Bioscience Inc. in Taiwan, where he contributed to the development of advanced cancer treatment solutions. Additionally, he has been associated with Beijing Pearl Biotechnology Limited Liability Company, further expanding his impact in the biotechnology sector.
Collaborations
Chuan Shih has collaborated with other talented individuals in the industry, including Boyu Zhong and Deyi Zhang. These collaborations illustrate the collective effort often needed to drive innovation in complex fields such as medical science and biotechnology.
Conclusion
Chuan Shih's contributions to the field of pharmacology through his patents reflect his commitment to improving cancer treatments. As an inventor with a vision for innovative solutions, Shih continues to inspire future advancements, encouraging further development in targeted therapies that can significantly enhance patient outcomes.